Cargando…
In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis
We describe two unrelated patients, a 12-yr-old female and a 6-yr-old male, with congenital contractures and severe congenital muscular atrophy. Exome and genome sequencing of the probands and their unaffected parents revealed that they have the same de novo deletion in BICD2 (c.1636_1638delAAT). Th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169820/ https://www.ncbi.nlm.nih.gov/pubmed/30054298 http://dx.doi.org/10.1101/mcs.a003160 |
_version_ | 1783360562109874176 |
---|---|
author | Koboldt, Daniel C. Kastury, Rama D. Waldrop, Megan A. Kelly, Benjamin J. Mosher, Theresa Mihalic McLaughlin, Heather Corsmeier, Don Slaughter, Jonathan L. Flanigan, Kevin M. McBride, Kim L. Mehta, Lakshmi Wilson, Richard K. White, Peter |
author_facet | Koboldt, Daniel C. Kastury, Rama D. Waldrop, Megan A. Kelly, Benjamin J. Mosher, Theresa Mihalic McLaughlin, Heather Corsmeier, Don Slaughter, Jonathan L. Flanigan, Kevin M. McBride, Kim L. Mehta, Lakshmi Wilson, Richard K. White, Peter |
author_sort | Koboldt, Daniel C. |
collection | PubMed |
description | We describe two unrelated patients, a 12-yr-old female and a 6-yr-old male, with congenital contractures and severe congenital muscular atrophy. Exome and genome sequencing of the probands and their unaffected parents revealed that they have the same de novo deletion in BICD2 (c.1636_1638delAAT). The variant, which has never been reported, results in an in-frame 3-bp deletion and is predicted to cause loss of an evolutionarily conserved asparagine residue at position 546 in the protein. Missense mutations in BICD2 cause autosomal dominant spinal muscular atrophy, lower-extremity predominant 2 (SMALED2), a disease characterized by muscle weakness and arthrogryposis of early onset and slow progression. The p.Asn546del clusters with four pathogenic missense variants in a region that likely binds molecular motor KIF5A. Protein modeling suggests that removing the highly conserved asparagine residue alters BICD2 protein structure. Our findings support a broader phenotypic spectrum of BICD2 mutations that may include severe manifestations such as cerebral atrophy, seizures, dysmorphic facial features, and profound muscular atrophy. |
format | Online Article Text |
id | pubmed-6169820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cold Spring Harbor Laboratory Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61698202018-10-12 In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis Koboldt, Daniel C. Kastury, Rama D. Waldrop, Megan A. Kelly, Benjamin J. Mosher, Theresa Mihalic McLaughlin, Heather Corsmeier, Don Slaughter, Jonathan L. Flanigan, Kevin M. McBride, Kim L. Mehta, Lakshmi Wilson, Richard K. White, Peter Cold Spring Harb Mol Case Stud Rapid Communication We describe two unrelated patients, a 12-yr-old female and a 6-yr-old male, with congenital contractures and severe congenital muscular atrophy. Exome and genome sequencing of the probands and their unaffected parents revealed that they have the same de novo deletion in BICD2 (c.1636_1638delAAT). The variant, which has never been reported, results in an in-frame 3-bp deletion and is predicted to cause loss of an evolutionarily conserved asparagine residue at position 546 in the protein. Missense mutations in BICD2 cause autosomal dominant spinal muscular atrophy, lower-extremity predominant 2 (SMALED2), a disease characterized by muscle weakness and arthrogryposis of early onset and slow progression. The p.Asn546del clusters with four pathogenic missense variants in a region that likely binds molecular motor KIF5A. Protein modeling suggests that removing the highly conserved asparagine residue alters BICD2 protein structure. Our findings support a broader phenotypic spectrum of BICD2 mutations that may include severe manifestations such as cerebral atrophy, seizures, dysmorphic facial features, and profound muscular atrophy. Cold Spring Harbor Laboratory Press 2018-10 /pmc/articles/PMC6169820/ /pubmed/30054298 http://dx.doi.org/10.1101/mcs.a003160 Text en © 2018 Koboldt et al.; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) , which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited. |
spellingShingle | Rapid Communication Koboldt, Daniel C. Kastury, Rama D. Waldrop, Megan A. Kelly, Benjamin J. Mosher, Theresa Mihalic McLaughlin, Heather Corsmeier, Don Slaughter, Jonathan L. Flanigan, Kevin M. McBride, Kim L. Mehta, Lakshmi Wilson, Richard K. White, Peter In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis |
title | In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis |
title_full | In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis |
title_fullStr | In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis |
title_full_unstemmed | In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis |
title_short | In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis |
title_sort | in-frame de novo mutation in bicd2 in two patients with muscular atrophy and arthrogryposis |
topic | Rapid Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169820/ https://www.ncbi.nlm.nih.gov/pubmed/30054298 http://dx.doi.org/10.1101/mcs.a003160 |
work_keys_str_mv | AT koboldtdanielc inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT kasturyramad inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT waldropmegana inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT kellybenjaminj inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT moshertheresamihalic inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT mclaughlinheather inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT corsmeierdon inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT slaughterjonathanl inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT flanigankevinm inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT mcbridekiml inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT mehtalakshmi inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT wilsonrichardk inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis AT whitepeter inframedenovomutationinbicd2intwopatientswithmuscularatrophyandarthrogryposis |